Revance Receives Great Place to Work Certification
September 20 2018 - 4:24PM
Business Wire
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology
company developing neuromodulators for use in treating aesthetic
and therapeutic conditions, today announced that the company was
certified as a great workplace this month by the independent
analysts at Great Place to Work®. Revance Therapeutics earned this
highly desirable credential based on a comprehensive set of ratings
provided by its employees in anonymous surveys.
“We are extremely proud to receive the designation as a great
workplace,” said Dan Browne, President and Chief Executive Officer
of Revance. “As a biotech company on the cusp of our first product
launch, we’ve worked through the long, challenging drug development
process to build a company dedicated to its people and its mission
to be a leader of innovation in neuromodulators. We’re committed to
creating a work environment and company culture where employees
contribute, grow and flourish on our journey to support patients
seeking better treatment options.”
About Great Place to Work Institute
Great Place to Work is a global research, consulting and
training firm that helps organizations create and sustain great
workplaces through the development of high-trust workplace
cultures. Great Place to Work serves business, non-profits and
government agencies in 45 countries on all six continents. In the
US, Great Place to Work produces the annual FORTUNE 100 Best
Companies to Work For list and Great Place to Work Best Small &
Medium Workplaces list published by Entrepreneur.com. Join the
movement of Great Place to Work at www.greatplacetowork.com.
About Revance Therapeutics, Inc.
Revance Therapeutics is an emerging Silicon Valley biotechnology
leader developing neuromodulators for the treatment of aesthetic
and therapeutic conditions. Revance uses a unique proprietary,
stabilizing excipient peptide technology to create novel,
differentiated therapies. The company’s lead compound,
DaxibotulinumtoxinA for Injection (RT002), is in clinical
development for a broad range of aesthetic and therapeutic
indications, including glabellar lines, cervical dystonia, plantar
fasciitis, upper limb spasticity and chronic migraine. RT002 has
the potential to be the first long-acting neuromodulator. The
company is advancing a robust pipeline of injectable and topical
formulations of DaxibotulinumtoxinA. More information on Revance
may be found at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered
trademarks of Revance Therapeutics, Inc.
Great Place to Work is a register trademark of Great Place to
Work® Institute.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements related to the process and timing of, and
ability to complete, current and anticipated future clinical
development of our investigational drug product candidates,
including but not limited to initiation and design of clinical
studies for current and future indications, including the timing
and results of the SAKURA 3 study of RT002 , related results and
reporting of such results; statements about our business strategy,
timeline and other goals and market for our anticipated products,
plans and prospects; including our pre-commercialization plans; and
statements about our ability to obtain regulatory approval,
including the timing of potential BLA filing for RT002 to treat
glabellar (frown) lines; and potential benefits of our drug product
candidates and our technologies.
Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially
from our expectations. These risks and uncertainties include, but
are not limited to: the outcome, cost, and timing of our product
development activities and clinical trials; the uncertain clinical
development process, including the risk that clinical trials may
not have an effective design or generate positive results; our
ability to obtain and maintain regulatory approval of our drug
product candidates; our ability to obtain funding for our
operations; our plans to research, develop, and commercialize our
drug product candidates; our ability to achieve market acceptance
of our drug product candidates; unanticipated costs or delays in
research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the
size and growth potential of the markets for our drug product
candidates; our ability to successfully commercialize our drug
product candidates and the timing of commercialization activities;
the rate and degree of market acceptance of our drug product
candidates; our ability to develop sales and marketing
capabilities; the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; our
ability to continue obtaining and maintaining intellectual property
protection for our drug product candidates; and other risks.
Detailed information regarding factors that may cause actual
results to differ materially from the results expressed or implied
by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange
Commission (the "SEC"), including factors described in the
section entitled "Risk Factors" of our quarterly report on Form
10-Q filed August 3, 2018. These forward-looking statements
speak only as of the date hereof. Revance disclaims any obligation
to update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180920005898/en/
INVESTORSRevance Therapeutics, Inc.:Jeanie Herbert,
714-325-3584jherbert@revance.comorBurns McClellan, Inc.:Ami
Bavishi, 212-213-0006abavishi@burnsmc.comorMEDIAGeneral
Media:TOGORUN:Mariann Caprino, 917-242-1087m.caprino@togorun.comorTrade Media:Nadine Tosk,
504-453-8344nadinepr@gmail.com
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Revance Therapeutics (NASDAQ:RVNC)
Historical Stock Chart
From Sep 2023 to Sep 2024